and €10 million in Lyon Gerland to produce Tzield (teplizumab), a biologic for type 1 diabetes that Sanofi acquired last year from Provention Bio in a $2.9 billion deal. “With these ...

Hospices Civils de Lyon) university hospital platform has been manufacturing the product as a magistral preparation, helping patients with the last remaining stock of active ingredient available from ...

LYON, France--(BUSINESS WIRE)--Osta Therapeutics ... Dr. Gilles Courtemanche brings more than 20 years of experience in drug development from positions at Rhône-Poulenc, Sanofi, and Synthelabo. Most ...

Fouque (CHU, Lyon-Sud) et L. Juillard (CHU Edouard Herriot ... since 2012 and Vifor France since 2018, Sanofi-Genzyme from 2012 to 2015, Baxter and Merck Sharp & Dohme-Chibret (MSD France) from 2012 ...

Sanofi has removed (PDF) a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers ...

Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L'Oréal, the first of multiple share buybacks the French drugmaker has planned for 2025. L'Oréal was selling 29,556,650 ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden child could be emerging in the form of Beyfortus. During its first ...

(Bloomberg) -- Sanofi said it will repurchase €5 billion ($5.2 billion) of stock and grow profits faster this year as the drugmaker pivots away from consumer health to focus on fast-growing ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212 ...

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

L’Oreal OR-1.27%decrease; red down pointing triangle will sell part of its stake in Sanofi SAN-0.21%decrease; red down pointing triangle back to the French pharmaceutical company for 3 billion ...

Patients to pay no more than $35 a month Eli Lilly, Sanofi previously settled overcharging claims Novo Nordisk denies wrongdoing, pledges affordable insulin Jan 27 (Reuters) - Novo Nordisk (NOVOb ...